Review Highlights Benefits, Drawbacks of Dual Biologic Therapy in Dermatology
This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.
Related Articles
HCPLive 5 Stories in Under 5: Week of 07/06
An audio recap of the top 5 stories in healthcare news from the week of 06/30-07/06.
Liver Lineup: Progress, Policy, and Barriers in Hepatitis C Elimination
Hosts Kimberly Brown and Nancy Reau discuss policy, clinical, and structural milestones enabling HCV elimination efforts and critical gaps impeding progress.
Review Highlights Benefits, Drawbacks of Dual Biologic Therapy in Dermatology
This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.
No Long-Term Dementia Risk Linked to Transient Ischemic Attack, 20-Year Study Finds
Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.
No Long-Term Dementia Risk Linked to Transient Ischemic Attack, 20-Year Study Finds
Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.
What’s New in Tardive Dyskinesia, With Jonathan Meyer, MD
Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.
FDA Approves Finerenone (Kerendia) for Heart Failure with Ejection Fraction of 40% or More
Finerenone gains FDA approval for heart failure treatment, offering new hope for patients with reduced ejection fraction and improving care options.
Q2 2025 Recap: Endocrinology News and Updates
Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.
New Insight: The eSight Go with Roland Mattern, eSight Director of Marketing
Veeral Sheth, MD, is joined by the director of marketing of eSight to discuss the 5th generation eSight Go, a device to enhance central vision…
No Long-Term Dementia Risk Linked to Transient Ischemic Attack, 20-Year Study Finds
Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.